NEW YORK, Oct. 9 – Sequitur has entered into an agreement with Procter and Gamble Pharmaceuticals to provide the company access to its functional genomics technology, the companies announced Tuesday.
Sequitur, based in Natick, Mass., will perform biological screening and supply its proprietary antisense compounds and methods to Procter and Gamble for use in its target validation studies as part of a multi-year agreement, according to the companies.
Financial details were not disclosed.